Literature DB >> 32057900

Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.

Shuang Zhao1, Ke Xu2, Rong Jiang1, Dan-Yang Li3, Xing-Xian Guo1, Peng Zhou1, Jia-Feng Tang1, Li-Sha Li1, Di Zeng1, Ling Hu4, Jian-Hua Ran4, Jing Li5, Di-Long Chen6.   

Abstract

AIMS: Dysfunction of the Hippo-Yes-Associated Protein (YAP) signaling pathway is known to be associated with hepatocellular carcinoma (HCC). Evodiamine (Evo), a plant-derived bioactive alkaloid, exerts inhibitory effects on cancer. However, the precise influence of Evo on HCC and its potential effects on Hippo-YAP signaling have yet to be ascertained. Here, the effects of Evo on cell proliferation and apoptosis were evaluated using HCC cell lines (HepG2 and Bel-7402) and nude mice with xenograft tumors. We further investigated whether Evo exerts anti-HCC activity through effects on Hippo-YAP signaling in vitro with the aid of XMU-MP-1, an inhibitor of the key component of this pathway, mammalian sterile 20-like kinase 1/2. MAIN
METHODS: Cell proliferation and apoptosis were assessed using 5-ethynyl-2'-deoxyuridine staining, colony formation, flow cytometry, hematoxylin-eosin and dUTP nick-end labeling experiments. Bioinformatics and real-time quantitative polymerase chain reaction (RT-qPCR) arrays were performed to determine the associations among Evo, HCC progression and the Hippo-YAP pathway. The expression patterns of components of Hippo-YAP signaling and apoptotic genes were further examined via RT-qPCR and immunoblotting. KEY
FINDINGS: Evo inhibited proliferation and promoted apoptosis of HCC cell lines in vitro, and attenuated xenograft tumor formation in nude mice in vivo. Mechanistically, Evo treatment stimulated the Hippo-YAP signaling pathway. In vitro, the effects of Evo on HCC cell proliferation and apoptosis were alleviated by XMU-MP-1. SIGNIFICANCE: Our collective results revealed that the anti-HCC effects of Evo were correlated with the Hippo-YAP signaling pathway.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-cancer effects; Evodiamine; Hepatocellular carcinoma; Hippo-YAP signaling pathway

Mesh:

Substances:

Year:  2020        PMID: 32057900     DOI: 10.1016/j.lfs.2020.117424

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

Review 1.  Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers.

Authors:  Munmun Panda; Surya Kant Tripathi; Gokhan Zengin; Bijesh K Biswal
Journal:  Cell Biol Toxicol       Date:  2022-09-23       Impact factor: 6.819

Review 2.  Emerging agents that target signaling pathways in cancer stem cells.

Authors:  Yue Yang; Xiaoman Li; Ting Wang; Qianqian Guo; Tao Xi; Lufeng Zheng
Journal:  J Hematol Oncol       Date:  2020-05-26       Impact factor: 17.388

3.  Chronic D-ribose and D-mannose overload induce depressive/anxiety-like behavior and spatial memory impairment in mice.

Authors:  Ke Xu; Mingyang Wang; Wei Zhou; Juncai Pu; Haiyang Wang; Peng Xie
Journal:  Transl Psychiatry       Date:  2021-02-02       Impact factor: 6.222

4.  Probing Synergistic Targets by Natural Compounds for Hepatocellular Carcinoma.

Authors:  Jian Gao; Zuojing Yin; Zhuanbin Wu; Zhen Sheng; Chao Ma; Rui Chen; Xiongwen Zhang; Kailin Tang; Jian Fei; Zhiwei Cao
Journal:  Front Cell Dev Biol       Date:  2021-07-28

5.  α-Hederin Inhibits the Proliferation of Hepatocellular Carcinoma Cells via Hippo-Yes-Associated Protein Signaling Pathway.

Authors:  Tongqing Chen; Dongdong Sun; Qijuan Wang; Tingting Zhou; Jiani Tan; Changliang Xu; Haibo Cheng; Weixing Shen
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

6.  A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine.

Authors:  Un-Jung Yun; Su-Jin Bae; Yu-Rim Song; Young-Woo Kim
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

Review 7.  Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway.

Authors:  Geofrey Mahiki Mranda; Zhi-Ping Xiang; Jun-Jian Liu; Tian Wei; Yinlu Ding
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

8.  Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis.

Authors:  Ze-Bo Jiang; Ju-Min Huang; Ya-Jia Xie; Yi- Zhong Zhang; Chan Chang; Huan-Ling Lai; Wenjun Wang; Xiao-Jun Yao; Xing-Xing Fan; Qi-Biao Wu; Chun Xie; Mei-Fang Wang; Elaine Lai-Han Leung
Journal:  J Exp Clin Cancer Res       Date:  2020-11-19

9.  The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.

Authors:  Liuyang Ren; Ying Lou; Mingyu Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

10.  Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.

Authors:  Yi Quan; Zhi Li; Kangshun Zhu; Jundi Liang
Journal:  Lipids Health Dis       Date:  2021-07-25       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.